Samenvatting
Summary Genome Technology and Applications
- Vak
- Instelling
This is a summary of the teachings of Prof Guy Van Camp, Frank Kooy and Wim Van Hul, based on the slides and notes.
[Meer zien]Voorbeeld 4 van de 57 pagina's
Voorbeeld 4 van de 57 pagina's
In winkelwagen
In winkelwagen
gesponsord bericht van onze partner
Verkoper
Volgen
BMWstudent19
Ontvangen beoordelingen
Voorbeeld van de inhoud
GENOME TECHNOLOGY AND APPLICATIONSINHOUD
1.1 Principles of DNA cloning ........................................................................................................................... 5
1.1.1 In vitro construction of a recombinant DNA molecule .......................................................................... 5
1.1.2 Transformation ...................................................................................................................................... 5
1.1.3 Selective propagation of clones ............................................................................................................. 6
1.1.4 Isolation of recombinant DNA clones .................................................................................................... 6
1.2 Restriction endonucleases ......................................................................................................................... 6
1.2.1 Cleavage................................................................................................................................................. 7
1.3 DNA ligase .................................................................................................................................................. 8
1.4 characteristics of the vector ...................................................................................................................... 8
1.4.1 Origin of replication (ORI) ...................................................................................................................... 8
1.4.2 Most used vectors ................................................................................................................................. 9
1.4.2.1 Plasmids ........................................................................................................................................ 9
1.4.2.2 Bacteriophages ............................................................................................................................. 9
1.4.3 Avoiding recircularisation ...................................................................................................................... 9
1.4.3.1 Use two different restriction enzymes ......................................................................................... 9
1.4.3.2 Dephosphorylate vector ............................................................................................................. 10
1.4.4 Recombinant screening ....................................................................................................................... 10
1.4.4.1 -galactosidase gene complementation ..................................................................................... 10
1.4.4.2 Suppressor tRNA genes ............................................................................................................... 11
1.4.5 Transformation .................................................................................................................................... 11
1.4.5.1 Classical plasmid preparation in E. coli ....................................................................................... 12
1.4.5.2 In vitro packaging ........................................................................................................................ 13
1.4.6 Lambda cloning vectors ....................................................................................................................... 13
1.4.6.1 Cosmid vectors ............................................................................................................................ 14
1.4.6.2 Bacteriophage P1 vectors ........................................................................................................... 14
1.4.6.3 BAC and PAC vectors ................................................................................................................... 14
1.4.6.4 Cloning in YACs (yeast artificial chromosomes) .......................................................................... 15
1.4.6.5 Overview vectors ........................................................................................................................ 15
1.4.6.6 M13 phages ................................................................................................................................ 16
1.4.6.7 Phagemid (phage-plasmid) vectors ............................................................................................ 16
1.4.6.8 Classical site-directed mutagenesis ............................................................................................ 17
2.1 Expression cloning in bacteria.................................................................................................................. 18
2.1.1 Fusion proteins .................................................................................................................................... 19
1
,2.2 Cloning in eukaryotes............................................................................................................................... 19
2.2.1 Double cassette vector and bicistronic vectors ................................................................................... 19
2.2.2 Two types of expression in eukaryotic cells ........................................................................................ 20
2.2.2.1 Transient expression ................................................................................................................... 20
2.2.2.2 Stable expression ........................................................................................................................ 20
2.2.2.3 Semi stable expression cloning using SV40................................................................................. 20
2.3 Expression in insect cells .......................................................................................................................... 21
2.4 Expression cloning using viral vectors ...................................................................................................... 21
2.4.1 Example of a viral vector: γ-Retrovirus ................................................................................................ 21
2.5 Stable expression in mammalian cells ..................................................................................................... 21
2.5.1 Functional complementation .............................................................................................................. 22
2.5.2 Dominant selectable marker ............................................................................................................... 22
2.6 Example of a classical expression cloning vector ..................................................................................... 22
2.7 Self study: new cloning methods ............................................................................................................. 23
2.7.1 Gateway cloning .................................................................................................................................. 23
2.7.1.1 Restriction enzymes vs. gateway ................................................................................................ 23
2.7.1.2 Target sequences for site-specific recombination ...................................................................... 23
2.7.1.3 Site-specific recombinase mechanism ........................................................................................ 24
2.7.1.4 Advantages ................................................................................................................................. 24
2.7.2 Gibson assembly .................................................................................................................................. 25
3.1 Introduction ............................................................................................................................................. 26
3.2 Start material PCR .................................................................................................................................... 27
3.2.1 Genomic DNA ...................................................................................................................................... 27
3.2.2 cDNA: RT PCR ....................................................................................................................................... 27
3.2.3 Primer design ....................................................................................................................................... 27
3.2.4 Temperature cycles ............................................................................................................................. 28
3.2.5 PCR mistakes........................................................................................................................................ 28
3.3 Types of PCR............................................................................................................................................. 28
3.3.1 Nested Primers .................................................................................................................................... 28
3.3.2 Hot start PCR ....................................................................................................................................... 29
3.3.3 Touch down PCR .................................................................................................................................. 29
3.3.4 Inverse PCR .......................................................................................................................................... 29
3.4 (Dis)advantages of PCR ............................................................................................................................ 30
3.4.1 Most important disadvantages of PCR ................................................................................................ 30
3.4.2 Most important advantages of PCR ..................................................................................................... 30
3.5 Cloning of PCR products ........................................................................................................................... 31
3.6 Allele specific PCR .................................................................................................................................... 31
2
, 3.6.1 ARMS assay .......................................................................................................................................... 31
3.6.2 DOP-PCR .............................................................................................................................................. 32
3.6.3 Alu PCR ................................................................................................................................................ 32
3.6.4 Linker primed PCR amplification ......................................................................................................... 32
3.6.5 Site-directed mutagenesis by PCR ....................................................................................................... 33
3.6.5.1 Add-on mutagenesis ................................................................................................................... 33
3.6.5.2 Mismatch primer mutagenesis ................................................................................................... 33
4.1 Model organisms ..................................................................................................................................... 34
4.1.1 Unicellular organisms .......................................................................................................................... 34
4.1.1.1 Bacteria ....................................................................................................................................... 34
4.1.1.2 Saccharomyces cerevisiae ........................................................................................................... 35
4.1.1.3 Mycoplasma genitalium .............................................................................................................. 35
4.1.2 Invertebrates ....................................................................................................................................... 35
4.1.2.1 Caenorhabditis elegans ............................................................................................................... 35
4.1.2.2 Drosophila Melanogaster............................................................................................................ 36
4.1.3 Vertebrates .......................................................................................................................................... 36
4.1.3.1 Zebrafish (Danio rerio) ................................................................................................................ 36
4.1.3.2 Xenopus ...................................................................................................................................... 37
4.1.3.3 Mammalian models .................................................................................................................... 37
4.2 comparative genomics ............................................................................................................................. 37
4.2.1 Explantations for conserved sequences .............................................................................................. 37
4.2.2 conserved sequences .......................................................................................................................... 38
4.3 Evolution .................................................................................................................................................. 39
4.3.1 Evolution of genomes .......................................................................................................................... 39
4.3.1.1 Duplications ................................................................................................................................ 39
4.3.1.2 Chromosomal rearrangements ................................................................................................... 42
4.3.2 Evolution trees..................................................................................................................................... 42
4.3.2.1 Comparison human-chimpansea genome .................................................................................. 42
4.4 Conclusions .............................................................................................................................................. 43
5.1 Introduction ............................................................................................................................................. 44
5.1.1 Personalized medicine ......................................................................................................................... 44
5.1.2 Pharmacogenetics ............................................................................................................................... 44
5.1.3 Aims of pharmacogenetics .................................................................................................................. 45
5.2 Possible explanations for differences in drug response .......................................................................... 45
5.3 Pharmacogenetic variation in drug metabolism ...................................................................................... 45
5.3.1 Oxidation: Cytochrome P-450 ............................................................................................................. 46
5.3.1.1 Genotype-phenotype relationship of the CYP2D6-polymorphism ............................................. 46
3
, 5.3.1.2 Amplichip CYP450 test ................................................................................................................ 46
5.3.1.3 CYP3A4 polymorphism ................................................................................................................ 46
5.3.1.4 Aldehyde dehydrogenase ........................................................................................................... 47
5.3.2 Acetylation: N-acetylation polymorphism NAT-2 ................................................................................ 47
5.3.3 Methylation: Thiopurine S-Methyltransferase .................................................................................... 47
5.4 Genetic differences in drug target ........................................................................................................... 48
5.4.1 Human growth hormone ..................................................................................................................... 48
5.4.2 β1-adrenerg receptor: sensitivity for β-blocking agents ..................................................................... 48
5.4.3 Warfarin ............................................................................................................................................... 48
5.5 Differentiation between subtypes of a disease ....................................................................................... 49
5.5.1 ERBB2 and herceptin ........................................................................................................................... 49
5.6 Preclinical drug development .................................................................................................................. 49
5.7 Expectations from pharmacogenetics ..................................................................................................... 51
5.7.1 Implementation in clinical practice ..................................................................................................... 51
5.7.1.1 Pilot projects for implementation ............................................................................................... 51
5.7.1.2 Interaction genome-diet ............................................................................................................. 51
6.1 Variation in the human genome .............................................................................................................. 52
6.2 Do we know other types of genomic variation? ...................................................................................... 52
6.2.1 Syndromes ........................................................................................................................................... 52
6.2.2 Fluorescent in situ hybridisation (FISH) ............................................................................................... 52
6.2.3 Principle of Array-CGH ......................................................................................................................... 52
6.3 Copy number variation ............................................................................................................................ 53
6.3.1 CNV is a subtype of Structural Variation ............................................................................................. 53
6.3.2 Mechanisms of rearrangements .......................................................................................................... 54
6.3.3 SNP array ............................................................................................................................................. 54
6.3.4 Examples .............................................................................................................................................. 55
6.3.4.1 The Williams-Beuren syndrome .................................................................................................. 55
6.3.4.2 17q21.31 microdeletion syndrome ............................................................................................. 55
7.1 Introduction ............................................................................................................................................. 56
7.2 Identifying novel, as yet unknown genetic disorders .............................................................................. 56
7.2.1 Trio approach....................................................................................................................................... 56
7.3 Would you not like to screen a large set of patients? ............................................................................. 57
4
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper BMWstudent19. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €8,99. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 79751 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen